DK0616536T3 - Anvendelse af decorin eller biglycan til fremstilling af et lægemiddel til behandling af diabetesbetingede tilstande - Google Patents
Anvendelse af decorin eller biglycan til fremstilling af et lægemiddel til behandling af diabetesbetingede tilstandeInfo
- Publication number
- DK0616536T3 DK0616536T3 DK93900930T DK93900930T DK0616536T3 DK 0616536 T3 DK0616536 T3 DK 0616536T3 DK 93900930 T DK93900930 T DK 93900930T DK 93900930 T DK93900930 T DK 93900930T DK 0616536 T3 DK0616536 T3 DK 0616536T3
- Authority
- DK
- Denmark
- Prior art keywords
- fibrosis
- growth factor
- biglycan
- decorin
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80328591A | 1991-12-04 | 1991-12-04 | |
PCT/US1992/010550 WO1993010808A1 (en) | 1991-12-04 | 1992-12-04 | INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0616536T3 true DK0616536T3 (da) | 1999-10-11 |
Family
ID=25186123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93900930T DK0616536T3 (da) | 1991-12-04 | 1992-12-04 | Anvendelse af decorin eller biglycan til fremstilling af et lægemiddel til behandling af diabetesbetingede tilstande |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0616536B1 (de) |
JP (2) | JP3854307B2 (de) |
AT (1) | ATE177644T1 (de) |
AU (2) | AU670770B2 (de) |
CA (1) | CA2124591A1 (de) |
DE (1) | DE69228700T2 (de) |
DK (1) | DK0616536T3 (de) |
FI (1) | FI942622A (de) |
NO (1) | NO942072L (de) |
WO (1) | WO1993010808A1 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2162586C (en) * | 1993-05-13 | 2006-01-03 | David J. Grainger | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
US5453492A (en) * | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
DE69434617D1 (de) * | 1993-11-19 | 2006-04-06 | Univ Sydney | Verfahren zur prophylaxe oder kontrolle des katarakts |
AU710153B2 (en) * | 1994-03-29 | 1999-09-16 | Renovo Limited | Wound healing |
US5824655A (en) * | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
DE19613691A1 (de) * | 1996-04-05 | 1997-10-09 | Boehringer Ingelheim Int | Arzneimittel für die Behandlung von Tumorerkrankungen |
AU1826799A (en) * | 1998-01-09 | 1999-07-26 | University Of Utah, The | Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by tgfbeta using renin inhibitors |
AU2008200019B2 (en) * | 1999-01-05 | 2009-10-08 | American National Red Cross | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
EP2130532A1 (de) | 1999-01-05 | 2009-12-09 | University of Utah Research Foundation | Verfahren zur Behandlung von mit der Akkumulation von überschüssiger extrazellulärer Matrix assoziierten Zuständen |
US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
US7612038B2 (en) | 1999-11-18 | 2009-11-03 | Brown University | Biglycan and related therapeutics and methods of use |
US6864236B1 (en) * | 1999-11-18 | 2005-03-08 | Brown University Research Foundation | Biglycan and related therapeutics and methods of use |
GB0102673D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
WO2003015615A2 (en) | 2001-08-15 | 2003-02-27 | Brown University Research Foundation | Treatment of muscular dystrophies and related disorders |
AU2003209308A1 (en) * | 2002-01-22 | 2003-09-02 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection |
WO2004075917A1 (ja) * | 2003-02-28 | 2004-09-10 | Toudai Tlo, Ltd. | 器官または組織の線維化抑制剤 |
ES2526705T3 (es) | 2005-10-25 | 2015-01-14 | The Johns Hopkins University | Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados |
WO2007108992A2 (en) | 2006-03-13 | 2007-09-27 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
EP1983345A1 (de) * | 2007-04-17 | 2008-10-22 | Roche Diagnostics GmbH | Mittel und Verfahren zur Bewertung des Risikos eines Herzeingriffs bei Patienten, die an einer auf GDF-15 basierenden stabilen Erkrankung der Herzkorona leiden |
HUE027831T2 (en) | 2010-03-12 | 2016-11-28 | Genzyme Corp | Combination therapy for breast cancer |
AU2011256256B2 (en) | 2010-05-17 | 2015-12-17 | Brown University | Biglycan mutants and related therapeutics and methods of use |
KR20130131414A (ko) | 2010-12-27 | 2013-12-03 | 엘에스아이피 환도 운에이고우도우가이샤 | iPS 세포와 그 제조법 |
US9958458B2 (en) | 2010-12-27 | 2018-05-01 | Brown University | Therapeutic and diagnostic methods involving biglycan and utrophin |
SG195253A1 (en) | 2011-06-03 | 2013-12-30 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
JP6218229B2 (ja) | 2011-12-28 | 2017-10-25 | 京都府公立大学法人 | 角膜内皮細胞の培養正常化 |
EP3064222B1 (de) | 2013-10-31 | 2020-10-21 | Kyoto Prefectural Public University Corporation | Therapeutikum enthaltend einen tgf-beta signalblocker für erkrankungen im zusammenhang mit endoplasmatischem retikulumszelltod im hornhautendothel |
WO2016187312A1 (en) | 2015-05-18 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
WO2017223268A1 (en) * | 2016-06-22 | 2017-12-28 | Yale University | COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi) |
JP7109039B2 (ja) | 2016-07-07 | 2022-07-29 | 国立大学法人千葉大学 | 抗線維症剤およびリン酸化Smad核内移行阻害剤 |
WO2019143219A1 (ko) * | 2018-01-22 | 2019-07-25 | 고려대학교 산학협력단 | 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물 |
KR102141125B1 (ko) * | 2018-01-22 | 2020-08-05 | 고려대학교 산학협력단 | 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물 |
FR3090320B1 (fr) * | 2018-12-19 | 2023-03-03 | Karim Bouzakri | Utilisation de la decorine dans le traitement du diabete |
WO2020209674A1 (ko) * | 2019-04-11 | 2020-10-15 | 고려대학교 산학협력단 | 비글리칸을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0494264T3 (da) * | 1989-09-29 | 1998-01-26 | Jolla Cancer Res Found | Inhibering af transformede vækstfaktor til hindring af akkumulation af ekstracellulær matrix |
WO1991010727A1 (en) * | 1990-01-22 | 1991-07-25 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors |
-
1992
- 1992-12-04 DK DK93900930T patent/DK0616536T3/da active
- 1992-12-04 WO PCT/US1992/010550 patent/WO1993010808A1/en active IP Right Grant
- 1992-12-04 EP EP93900930A patent/EP0616536B1/de not_active Expired - Lifetime
- 1992-12-04 DE DE69228700T patent/DE69228700T2/de not_active Expired - Lifetime
- 1992-12-04 AT AT93900930T patent/ATE177644T1/de not_active IP Right Cessation
- 1992-12-04 JP JP51038393A patent/JP3854307B2/ja not_active Expired - Lifetime
- 1992-12-04 AU AU32429/93A patent/AU670770B2/en not_active Expired
- 1992-12-04 CA CA002124591A patent/CA2124591A1/en not_active Abandoned
-
1994
- 1994-06-03 FI FI942622A patent/FI942622A/fi not_active Application Discontinuation
- 1994-06-03 NO NO942072A patent/NO942072L/no unknown
-
1996
- 1996-10-25 AU AU70518/96A patent/AU7051896A/en not_active Abandoned
-
2003
- 2003-10-31 JP JP2003373712A patent/JP2004043507A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
FI942622A (fi) | 1994-07-27 |
EP0616536A1 (de) | 1994-09-28 |
DE69228700D1 (de) | 1999-04-22 |
ATE177644T1 (de) | 1999-04-15 |
WO1993010808A1 (en) | 1993-06-10 |
DE69228700T2 (de) | 1999-09-09 |
FI942622A0 (fi) | 1994-06-03 |
CA2124591A1 (en) | 1993-06-10 |
AU3242993A (en) | 1993-06-28 |
JPH07504650A (ja) | 1995-05-25 |
JP2004043507A (ja) | 2004-02-12 |
EP0616536B1 (de) | 1999-03-17 |
AU670770B2 (en) | 1996-08-01 |
NO942072L (no) | 1994-08-03 |
JP3854307B2 (ja) | 2006-12-06 |
AU7051896A (en) | 1997-01-16 |
NO942072D0 (no) | 1994-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0616536T3 (da) | Anvendelse af decorin eller biglycan til fremstilling af et lægemiddel til behandling af diabetesbetingede tilstande | |
ATE193541T1 (de) | Insulinotropes hormon | |
JP5528380B2 (ja) | 修飾されたエキセンディン(Exendins)及びその使用 | |
Barragan et al. | Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats | |
DE69327309T2 (de) | Verwendung eines peptids | |
ATE372782T1 (de) | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes | |
RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
PT1146896E (pt) | Formulacoes monodispersas de analogo acilado e hexamerico insulina | |
DE69930974D1 (de) | Systeme und Präparate zur Medikamentenabgabe an interstitielle Regionen des Myokardiums | |
CY1110445T1 (el) | Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενεια | |
Okabe et al. | Wound treatment using growth factors | |
Doi et al. | Vascular endothelial growth factor suppresses C-type natriuretic peptide secretion | |
EP3351561A1 (de) | Adrenomedullinderivat mit langzeitwirkung | |
DK47089A (da) | Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer | |
RU2005135428A (ru) | Поглощение макромолекул | |
ES2092698T3 (es) | Metodo terapeutico para el tratamiento de la diabetes mellitus dependiente de insulina (iddm). | |
Paunio et al. | The effect of chlorhexidine gluconate on the formation of experimental granulation tissue. | |
Jeffcott et al. | The treatment of horses with chronic back pain by resecting the summits of the impinging dorsal spinous processes | |
Burk | Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO) | |
EP0320785A3 (de) | Peptide mit beeinflussender Wirkung auf die Hypophyse von Säugern | |
Ugalde et al. | Ischemic peripheral neuropathy | |
Capanna et al. | Hemipelvectomy in malignant neoplasms of the hip region. | |
NZ513087A (en) | Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease | |
Stuermer et al. | Raloxifene supports early fracture healing more than estrogen in ovariectomized rats | |
Müller et al. | Expandable metal mesh stents for treatment of tracheal stenoses and tracheomalacia |